


## AMENDMENTS TO THE CLAIMS

1. (Currently Amended) A tetrahydrobenzazepine of the ~~general~~ formula I



in which

A ~~—~~ is a single bond or  $\text{CH}_3$ :

~~B~~ is a single bond or a group  $\text{NR}_3^+$ ;

~~Y — is a single bond,  $\text{CH}_2$  or a group  $\text{NR}^2$ , where A, B and Y are not simultaneously a single bond;~~

Ar is an aromatic radical which is selected from phenyl and a 5- or 6-membered heteroaromatic radical having 1, 2, 3 or 4 heteroatoms which are selected independently of one another from O, N and S, where the aromatic radical may have 1, 2 or 3 substituents which are selected independently of one another from  $C_1$ - $C_6$ -alkyl which is optionally substituted one or more times by OH,  $C_1$ - $C_4$ -alkoxy, halogen or phenyl, or  $C_2$ - $C_6$ -alkenyl which is optionally substituted one or more times by OH,  $C_1$ - $C_4$ -alkoxy, halogen or phenyl, or  $C_2$ - $C_6$ -alkynyl which is optionally substituted one or more times by OH,  $C_1$ - $C_4$ -alkoxy, halogen or phenyl, or  $C_3$ - $C_6$ -cycloalkyl which is optionally substituted one or more times by OH,  $C_1$ - $C_4$ -alkoxy, halogen, phenyl or  $C_1$ - $C_4$ -alkyl, or halogen, CN, OR<sup>4</sup>, COOR<sup>4</sup>, NR<sup>5</sup>R<sup>6</sup>, CONR<sup>5</sup>R<sup>6</sup>, NO<sub>2</sub>, SR<sup>7</sup>, SO<sub>2</sub>R<sup>7</sup>, SO<sub>2</sub>NR<sup>5</sup>R<sup>6</sup>, COR<sup>8</sup>, and phenyl which optionally has one, two or three substituents which are selected independently of one another from  $C_1$ - $C_4$ -alkyl,

$C_1$ - $C_4$ -alkoxy,  $NR^5R^6$ , CN,  $C_1$ - $C_2$ -fluoroalkyl or halogen, where phenyl and the heterocyclic radical may also be fused to a 5- or 6-membered aromatic or nonaromatic carbocycle, or phenyl may be fused to a 5- or 6-membered aromatic or nonaromatic heterocycle which has 1, 2 or 3 heteroatoms selected from O, N and S;

$R^1$  is hydrogen,  $C_1$ - $C_8$ -alkyl,  $C_1$ - $C_8$ -haloalkyl,  $C_2$ - $C_8$ -alkenyl,  $C_2$ - $C_8$ -haloalkenyl,  $C_2$ - $C_8$ -alkynyl,  $C_2$ - $C_8$ -haloalkynyl,  $C_1$ - $C_8$ -alkylcarbonyl,  $C_1$ - $C_8$ -haloalkylcarbonyl or substituted  $C_1$ - $C_8$ -alkyl which carries a substituent which is selected from OH,  $C_1$ - $C_4$ -alkoxy,  $C_1$ - $C_4$ -alkylamino,  $\text{Didi-}(C_1-C_4\text{-alkyl})\text{amino}$ , phenyl, phenoxy,  $C_3$ - $C_8$ -cycloalkyl and  $C_3$ - $C_8$ -cycloalkyloxy, where the last four groups mentioned may optionally have one or more substituents selected from OH, CN,  $NO_2$ ,  $C_1$ - $C_4$ -alkyl,  $C_1$ - $C_4$ -haloalkyl,  $C_1$ - $C_4$ -alkoxy,  $C_1$ - $C_4$ -haloalkoxy and halogen;

$R^2$  is hydrogen, halogen,  $C_1$ - $C_4$ -alkyl,  $C_1$ - $C_4$ -alkoxy,  $C_1$ - $C_4$ -haloalkyl,  $C_1$ - $C_4$ -haloalkoxy, OH,  $NO_2$ , CN,  $COOR^4$ ,  $NR^5R^6$  or  $CONR^5R^6$ ;

$R^3$  is hydrogen,  $C_1$ - $C_4$ -alkyl,  $C_1$ - $C_4$ -alkoxy,  $C_1$ - $C_4$ -alkylcarbonyl, phenyl, phenyl- $C_1$ - $C_4$ -alkyl or phenylcarbonyl, where phenyl in the last three radicals mentioned may optionally have 1, 2 or 3 substituents which are selected independently of one another from  $C_1$ - $C_4$ -alkyl,  $C_1$ - $C_4$ -haloalkyl,  $C_1$ - $C_4$ -alkoxy and halogen;

$R^4$ ,  $R^5$ ,  $R^6$ ,  $R^7$ , and  $R^8$  are independently of one another H,  $C_1$ - $C_6$ -alkyl which may carry a substituent selected from OH,  $C_1$ - $C_4$ -alkoxy and optionally substituted phenyl,  $C_1$ - $C_6$ -haloalkyl or phenyl, where  $R^6$  may also be a group  $COR^9$  in which  $R^9$  is H,  $C_1$ - $C_6$ -alkyl which is optionally substituted by OH,  $C_1$ - $C_4$ -alkoxy or optionally substituted phenyl, or  $C_1$ - $C_6$ -haloalkyl or phenyl, where

$R^5$  with  $R^6$  may also together with the nitrogen atom to which they are bonded be a 5- or 6-membered saturated or unsaturated N-heterocycle which may optionally have a further heteroatom selected from O, S and  $NR^{10}$  as ring member, where  $R^{10}$  is hydrogen or  $C_1$ - $C_4$ -alkyl;

the N-oxides of this compound, the physiologically tolerated acid addition salts of this compound and the physiologically tolerated acid addition salts of the N-oxides of formula I.

2. (Canceled)

3. (Canceled)

4. (Canceled)

5. (Canceled)


6. (Currently Amended) A tetrahydrobenzazepine of the general formula I as claimed in claim 1, in which R2 is hydrogen.

7. (Currently Amended) A tetrahydrobenzazepine of the general formula I as claimed in claim 1, in which Ar is phenyl which may be substituted ~~in the abovementioned manner as claimed in claim 1.~~

8. (Currently Amended) A tetrahydrobenzazepine of the general formula I as claimed in claim 7, in which phenyl is unsubstituted or has 1 or 2 substituents, of which one substituent is arranged in the para position relative to the variable YNR<sup>3</sup>.

9. (Currently Amended) A tetrahydrobenzazepine of the general formula I as claimed in claim 7, in which the substituents on the phenyl are selected from C<sub>2</sub>-C<sub>6</sub>-alkyl, C<sub>2</sub>-C<sub>6</sub>-alkenyl, C<sub>2</sub>-C<sub>6</sub>-alkynyl and C<sub>1</sub>-C<sub>2</sub>-fluoroalkyl.

10. (Original) A compound as claimed in claim 1, wherein Ar is phenyl which carries a radical R<sup>P</sup> which is located in the para position of the phenyl ring wherein R<sup>P</sup> has the following formula R<sup>P</sup>:



wherein

Y is N, CH or CF,

R<sup>a1</sup> and R<sup>a2</sup> are independently of each other selected from C<sub>1</sub>-C<sub>2</sub>-alkyl, fluorinated C<sub>1</sub>-C<sub>2</sub>-alkyl, provided for Y being CH or CF one of the radicals R<sup>a1</sup> or R<sup>a2</sup> may also be hydrogen or fluorine, or

R<sup>a1</sup> and R<sup>a2</sup> form a radical (CH<sub>2</sub>)<sub>m</sub> wherein 1 or 2 of the hydrogen atoms may be replaced by fluorine and wherein m is 2, 3 or 4.

11. (Currently Amended) A tetrahydrobenzazepine of the ~~general~~ formula I as claimed in claim 1, in which Ar is a 5- or 6-membered heteroaromatic radical having 1, 2, 3 or 4 heteroatoms which are selected independently of one another from O, N and S, where the heteroaromatic radical may be substituted ~~in the abovementioned manner as claimed in claim 1.~~


12. (Currently Amended) A tetrahydrobenzazepine of the ~~general~~ formula I as claimed in claim 1, in which R<sup>1</sup> has the ~~general~~ formula CH<sub>2</sub>-R<sup>1a</sup> in which R<sup>1a</sup> is C<sub>1</sub>-C<sub>7</sub>-alkyl, C<sub>1</sub>-C<sub>7</sub>-haloalkyl, C<sub>2</sub>-C<sub>7</sub>-alkenyl, C<sub>2</sub>-C<sub>7</sub>-haloalkenyl, C<sub>2</sub>-C<sub>7</sub>-alkynyl, C<sub>2</sub>-C<sub>7</sub>-haloalkynyl or C<sub>1</sub>-C<sub>7</sub>-alkyl which has a substituent which is selected from OH, C<sub>1</sub>-C<sub>4</sub>-alkoxy, C<sub>1</sub>-C<sub>4</sub>-alkylamino, di-(C<sub>1</sub>-C<sub>4</sub>-alkyl)amino, phenyl, phenoxy, C<sub>3</sub>-C<sub>8</sub>-cycloalkyl and C<sub>3</sub>-C<sub>8</sub>-cycloalkyloxy, where the last four groups mentioned may optionally have one or more substituents selected from C<sub>1</sub>-C<sub>4</sub>-alkyl, C<sub>1</sub>-C<sub>4</sub>-haloalkyl, C<sub>1</sub>-C<sub>4</sub>-alkoxy and halogen, ~~or~~ C<sub>4</sub>-C<sub>4</sub>-alkoxy, C<sub>4</sub>-C<sub>4</sub>-alkylamino, di-C<sub>4</sub>-C<sub>4</sub>-alkylamino, phenyl, phenoxy, C<sub>3</sub>-C<sub>8</sub>-cycloalkyl or C<sub>3</sub>-C<sub>8</sub>-cycloalkyloxy, where the last four groups mentioned may optionally have one or more substituents selected from C<sub>4</sub>-C<sub>4</sub>-alkyl, C<sub>4</sub>-C<sub>4</sub>-haloalkyl, C<sub>4</sub>-C<sub>4</sub>-alkoxy, C<sub>4</sub>-C<sub>4</sub>-haloalkoxy and halogen.

13. (Currently Amended) A tetrahydrobenzazepine of the ~~general~~ formula I as claimed in claim 112, in which R<sup>1a</sup> is C<sub>1</sub>-C<sub>7</sub>-alkyl, C<sub>2</sub>-C<sub>7</sub>-alkenyl, C<sub>2</sub>-C<sub>7</sub>-alkynyl, C<sub>3</sub>-C<sub>8</sub>-cycloalkyl or C<sub>1</sub>-C<sub>7</sub>-fluoroalkyl.

14. (Canceled)

15. (Canceled)

16. (Currently Amended) A tetrahydrobenzazepine as claimed in claim 441, wherein  $R^P$  is selected from a radical of the formula



wherein

$Y$  is N, CH or CF,

$R^{a1}$  and  $R^{a2}$  are independently of each other selected from  $C_1$ - $C_2$ -alkyl, fluorinated  $C_1$ - $C_2$ -alkyl, provided for  $Y$  being CH or CF one of the radicals  $R^{a1}$  or  $R^{a2}$  may also be hydrogen or fluorine, or

$R^{a1}$  and  $R^{a2}$  form a radical  $(CH_2)_m$  wherein 1 or 2 of the hydrogen atoms may be replaced by fluorine and wherein  $m$  is 2, 3 or 4; and  $R^{1a}$  is ethyl.

17. (Original) A tetrahydrobenzazepine as claimed in claim 16, wherein  $R^P$  is selected from isopropyl, (R)-1-fluoroethyl, (S)-1-fluoroethyl, 2-fluoroethyl, 1,1-difluoroethyl, 2,2-difluoroethyl, 2,2,2-trifluoroethyl, (R)-1-fluoropropyl, (S)-1-fluoropropyl, 2-fluoropropyl, 3-fluoropropyl, 1,1-difluoropropyl, 2,2-difluoropropyl, 3,3-difluoropropyl, 3,3,3-trifluoropropyl, (R)-2-fluoro-1-methylethyl, (S)-2-fluoro-1-methylethyl, (R)-2,2-difluoro-1-methylethyl, (S)-2,2-difluoro-1-methylethyl, (R)-1,2-difluoro-1-methylethyl, (S)-1,2-difluoro-1-methylethyl, (R)-2,2,2-trifluoro-1-methylethyl, (S)-2,2,2-trifluoro-1-methylethyl, 2-fluoro-1-(fluoromethyl)ethyl, 1-(difluoromethyl)-2,2-difluoroethyl, 1-fluoro-1-methylethyl, cyclopropyl, cyclobutyl, 1-fluorocyclopropyl, 2,2-difluorocyclopropyl and 2-fluorocyclopropyl.

18. (Currently Amended) A pharmaceutical composition comprising at least one active ingredient selected from compound of the general formula I as claimed in claim 1, the physiologically tolerated acid addition salts of formula I, the N-oxides of compounds of the general

formula I, and the physiologically tolerated acid addition salts of the N-oxides of formula I, where appropriate together with physiologically acceptable carriers and/or excipients.

19. (Canceled)

20. (Canceled)

21. (Canceled)

22. (Currently Amended) A method for treating a medical disorder susceptible to treatment with a dopamine D3 receptor ligand, said method comprising administering an effective amount of at least one compound as claimed in claim 1 to a subject in need thereof, wherein the medical disorder is selected from the group consisting of schizophrenia, depression, parkinsonism, and renal function disorders.

23. (Currently Amended) The method as claimed in claim 22, wherein the medical disorder is a disease of the central nervous system selected from the group consisting of schizophrenia, depression and parkinsonism.

24. (New) The method as claimed in claim 22, wherein the medical disorder is a renal function disorders.